Differential expression of estradiol and estrogen receptor α in severe preeclamptic pregnancies compared with normal pregnancies

GUOWU YIN\textsuperscript{1}, XIAOMING ZHU\textsuperscript{1}, CHUN GUO\textsuperscript{2}, YANG YANG\textsuperscript{3}, TAO HAN\textsuperscript{4}, LEI CHEN\textsuperscript{1}, WEN YIN\textsuperscript{5}, PING GAO\textsuperscript{1}, HUIZHONG ZHANG\textsuperscript{6}, JIE GENG\textsuperscript{7}, JULEI WANG\textsuperscript{8} and LIANG LIANG\textsuperscript{9}

\textsuperscript{1}Department of Obstetrics and Gynecology, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shanxi 710038; \textsuperscript{2}Department of Obstetrics and Gynecology, Armed Police Corps Hospital, Hohhot, Inner Mongolia 010040; \textsuperscript{3}Department of Obstetrics and Gynecology, Affiliated Hospital of Xi'an Medical University, Xi'an, Shanxi 710077; \textsuperscript{4}Department of Orthopedics, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shanxi 710038; \textsuperscript{5}Department of Microbiology, School of Preclinical Medicine, Fourth Military Medical University, Xi'an, Shanxi 710032; Departments of \textsuperscript{6}Medical Laboratory, \textsuperscript{7}Teaching and Medical Administration and \textsuperscript{8}Neurosurgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shanxi 710038; \textsuperscript{9}Department of Medical Genetics and Developmental Biology, Fourth Military Medical University, Xi'an, Shanxi 710032, P.R. China

Received August 14, 2012; Accepted November 13, 2012

DOI: 10.3892/mmr.2013.1262

Abstract. The purpose of this study was to investigate the expression of estradiol and estrogen receptor α (ESRα) in severe preeclamptic (sPE) pregnancies compared with normal pregnancies. Sera and placentas were obtained from i) patients with sPE (n=25) and ii) a normal control group (n=25) who underwent elective Cesarean deliveries. Estradiol expression was assessed by enzyme-linked immunosorbent assays (ELISAs). ESRα expression was assessed by reverse transcription polymerase chain reaction (RT-PCR) analysis and western blot analysis. In preeclamptic pregnancies, estradiol was underexpressed (P<0.05), however, ESRα mRNA and protein levels were increased significantly in comparison with normal pregnancies (P<0.05). These results show that estradiol and ESRα are deregulated in preeclamptic pregnancies, which in turn suggests the involvement of these molecules in the pathogenesis of preeclampsia.

Introduction

Preeclampsia is a common pregnancy-specific syndrome that is characterized by hypertension and proteinuria. It is a disorder that affects at least 5% of all pregnancies worldwide (1) and is a leading cause of maternal and perinatal morbidity and mortality. Although the cause of preeclampsia remains unclear, it is generally agreed that preeclampsia results from the presence of a placenta (2) since the only treatment for preeclampsia is the delivery of the placenta, subsequent to which the symptoms regress rapidly. Previous studies in our laboratory have demonstrated that miR-18a was downregulated in preeclamptic placentas (3). miR-18a is a component of the miR-17-92 gene cluster which is located on chromosome 13q31.3. Evidence has shown that the ESR1 gene, which encodes estrogen receptor α (ESRα), is a target of miR-18a (4).

Estrogen receptors (ESRs) are members of the nuclear receptor superfamily that mediate the pleiotropic effects of the steroid hormone estrogen in a diverse range of developmental and physiological processes (5). There are two forms of the ESR, ESRα and ESRβ, each encoded by a separate gene (ESR1 and ESR2, respectively). ESRα is expressed mainly in the ovaries, uterus and placenta (6), while ESRβ is widely expressed in a number of tissues (7). The receptors are activated by the hormone 17β-estradiol (6,7). Liu et al identified that miR-18a prevents translation of ESRα by binding to its mRNA at the 3’ untranslated region, potentially blocking the protective effects of estrogen (4). These previous study findings suggest that miR-18a may be involved in the pathogenesis of preeclampsia through regulation of ESRα, which in turn suggests the involvement of ESRα and 17β-estradiol in the pathogenesis of preeclampsia.

A certain degree of attention has been given to ESRα, 17β-estradiol and preeclampsia. However, studies measuring ESRα and 17β-estradiol from preeclamptic females have demonstrated inconsistent results, with certain studies revealing differential ESRα and estradiol expression in preeclampsia (8,9) while others have shown no differences (10-12). For these reasons, we investigated the expression of estradiol and ESRα in severe preeclamptic (sPE) pregnancies compared with normal

Correspondence to: Dr Xiaoming Zhu, Department of Obstetrics and Gynecology, Tangdu Hospital, Fourth Military Medical University, Xins Street, Xi’an, Shanxi 710038, P.R. China

E-mail: xiaomingzhu1981@hotmail.com

*Contributed equally

Key words: estradiol, estrogen receptor α, preeclampsia, pregnancy
pregnancies, with the hope that such associations may provide insights into the causal mechanisms of preeclampsia.

Materials and methods

Sample collection and hormone assay. Sera and placental tissues were obtained with informed consent from nulliparous females who were admitted to the Department of Obstetrics and Gynecology, Tangdu Hospital in Xi'an, China. The samples were obtained from patients with normal pregnancies (control group; n=25) and from patients with sPE (sPE group; n=25). All females underwent an elective Cesarean delivery in the absence of labor; the clinical characteristics of the study groups are shown in Table I. Preeclampsia was defined according to the criteria of the International Society for the Study of Hypertension in Pregnancy (13,14). sPE was defined as either severe hypertension (systolic blood pressure of ≥160 mmHg and/or diastolic blood pressure of ≥110 mmHg on at least 2 occasions 6 h apart) plus mild proteinuria (>0.3 g/24 h or >1+ by dipstick), or as mild hypertension (systolic blood pressure of ≥140 mmHg and/or diastolic blood pressure of ≥90 mmHg on at least 2 occasions 6 h apart) plus severe proteinuria (>2 g/24 h or >2+ by dipstick) (13,14). No other maternal complications arose in any of the preeclamptic pregnancies, and none of our subjects had a birthweight of <10% of average birthweight.

Table I. Clinical characteristics of normal and preeclamptic pregnancies.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Control (n=25)</th>
<th>sPE (n=25)</th>
<th>P-value* control vs. sPE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal age (years)</td>
<td>30.8±2.1</td>
<td>31±1.9</td>
<td>0.912</td>
</tr>
<tr>
<td>Gestational age (weeks)</td>
<td>37.5±2.0</td>
<td>36±2.7</td>
<td>0.094</td>
</tr>
<tr>
<td>Birth weight (g)</td>
<td>3151±386</td>
<td>3009±497</td>
<td>0.314</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>24.9±2.3</td>
<td>24.1±2.4</td>
<td>0.081</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>110.1±9.2</td>
<td>169.6±26.2</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>69.1±8.2</td>
<td>112.9±17.5</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Proteinuria (g/24 h)</td>
<td>0</td>
<td>2.9±1.5</td>
<td>&lt;0.01</td>
</tr>
</tbody>
</table>

All results are presented as mean ± SD. sPE, severe preeclampsia. *One-way ANOVA showed a statistically significant distribution of P-values.

Table II. Primer sequences and reaction conditions for RT-PCR.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Primer sequences</th>
<th>Annealing temperature (˚C)</th>
<th>Cycle (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ESRα</td>
<td>F: CCTGGCTAGAGATCCTGAT R: CCCCTGGTTCCTGTCACAGA</td>
<td>56</td>
<td>31</td>
</tr>
<tr>
<td>β-actin</td>
<td>F: TCATCACTATTTGGCAACGAGC A: AACAGTCCGCTAGAAGGCAC</td>
<td>55</td>
<td>25</td>
</tr>
</tbody>
</table>

RT-PCR, reverse transcription polymerase chain reaction; F, forward; R, reverse.

Reverse transcription polymerase chain reaction (RT-PCR) analysis. RT-PCR analysis was performed on 50 tissue samples, one obtained from each subject. The total RNA was isolated from the placentas using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. The purity and concentration of the total RNA were measured on a spectrophotometer (Jenway Ltd., Bibby Scientific Limited, Staffordshire, UK) using their absorbance values (260/280 nm). RNA integrity was confirmed by electrophoresis in a 1.5% agarose denaturing gel and 1 µg total RNA was subsequently reverse transcribed into cDNA using a RevertAid™ First Strand cDNA Synthesis kit (MBI, Fermentas, Vilnius, Lithuania).

The primers for the RT-PCR were designed according to specific cDNA sequences in the NCBI database (ESRα, accession no: NM_000125; β-actin, accession no: NM_001101). The primer sequences and the reaction conditions are shown in Table II. A 25-µl PCR master mix was prepared as follows: 1 µl RT products, 200 µmol/l dNTPs, 2 mMol/l MgCl₂, 1 IU Taq DNA polymerase and 10 pmol of each primer.

Amplification was ensured to occur within the exponential phase of PCR using preliminary experiments. PCR products
were subjected to electrophoresis on agarose gels and the relative densities of ESRα genes normalized to β-actin were analyzed using the Image-Pro plus (software version 6.0; Media Cybernetics, Silver Spring, MD, USA).

**Western blot analysis.** Tissues were homogenized and incubated on ice in PRO-PREP™ Protein Extraction Solution (SBS, Beijing, China). The supernatant was collected and protein estimation was carried out using the Bradford method. A total of 50 µg of protein per lane was used for western blot analysis. All proteins were heated at 100°C and separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on a 10% gel. The proteins were next transferred to a polyvinylidene difluoride membrane (Hybond, Amersham Biosciences, Little Chalfont, UK) by semi-dry electroblotting. Nonspecific reactivity was blocked by placing the membrane in 5% skimmed milk in PBST. The membrane was then incubated with rabbit antibodies against human ESRα (1:2,500, Epitomic, Burlingame, CA, USA). The membrane was subsequently washed in PBST and incubated with horseradish peroxidase secondary antibody (1:5,000, Kangwei, Beijing, China). Chemiluminescent detection was carried out using the Enhanced Chemiluminescent Substrate (Pierce, Rockford, IL, USA). Subsequent to stripping, the same membrane was used to reprobe with the rabbit-anti-human β-actin antibody (1:3,000, Abcam, Cambridge, UK) to detect β-actin as the internal loading control.

**Statistical analysis.** All values are presented as the mean ± SD of three individual experiments performed in triplicate. Comparison of the values between groups was performed using one-way ANOVA by SPSS 11.0 software. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Estradiol expression in normal and preeclamptic serum samples.** Estradiol serum concentrations that were measured in the 25 normal pregnant females ranged between 23.06 and 85.90 ng/ml, with a median value of 53.220 ng/ml. By contrast, estradiol serum concentrations that were measured in the 25 patients with preeclampsia ranged between 9.54 and 59.15 ng/ml, with a median value of 29.550 ng/ml. The estradiol serum concentrations were significantly lower in the preeclamptic pregnant females than in the normal pregnant females (29.550±11.172 vs. 53.220±16.560 ng/ml, respectively; independent t-test: P<0.05; Fig. 1).

**ESRα expression in normal and preeclamptic chorionic villi.** We compared the expression levels of ESRα mRNA in chorionic villi from normal pregnancies with those from patients...
with sPE using RT-PCR analysis. Relative expression of ESRα was calculated by normalizing to β-actin expression. The mean level of ESRα mRNA in the preeclamptic chorionic villi was significantly higher than that of normal controls (P<0.05: 0.43±0.067 (sPE) and 0.20±0.044 (control) by densitometric quantitation (Fig. 2).

To determine whether the mRNA levels correlated with the amount of ESRα protein, we measured the ESRα protein expression by western blot analysis. Similar results were obtained as shown in Fig. 3; the mean level of ESRα protein corrected by β-actin protein was significantly higher in the preeclamptic villi than that in normal controls (P<0.05): 0.98±0.047 (sPE) and 0.61±0.061 (control) by densitometric quantitation.

**Discussion**

The present study demonstrated a significant decrease in the expression of estradiol in patients with sPE, and a significant increase of ESRα expression in preeclamptic pregnancies compared with normal pregnancies.

The estrogens are a group of sex hormones secreted primarily by the ovaries, however, during pregnancy estrogen is secreted by the placenta. Estrogen is involved in the development and maintenance of the female phenotype, germ cell maturation and pregnancy. There are several types of estrogen but the three main types are estrone (E1), estradiol (E2) and estriol (E3). At equal concentrations, E2 has a stronger biological effect than E1 which in turn is more powerful than E3 (15). We therefore investigated the E2 level (but not E1 or E3) by enzyme-linked immunosorbent assay (ELISA) analysis, and detected that E2 was underexpressed in preeclamptic pregnancies when compared with normal pregnancies. These results are similar to the findings recorded by Zeisler et al and Hertig et al (9,16). Normal pregnancy itself is a state of systemic inflammation with an elevation in the white blood cell count. However, the immune system is suppressed during normal pregnancy in order to protect the fetus against immune cell lysis. It is generally agreed that there is an activated systemic maternal inflammatory response in preeclampsia (17) that affects the circulating leukocytes, and that circulating IL-6 and IL-8 are increased in preeclampsia. Evidence indicates that estradiol has an anti-inflammatory effect (18). Schaefer et al observed that estradiol has an inhibitory effect on IL-1β-mediated inflammatory responses in uterine epithelial cells, which suggests a link between the endocrine and immune systems, and indicates that estradiol may be crucial for protecting the fetus against immune cells lysis during pregnancy (19). Therefore, the significant decrease in the expression of estradiol in patients with sPE may impair this ability to protect the fetus against immune cells lysis.

Estrogens mediate their action on a target tissue by binding to their receptors, which are nuclear transcription factors. To date, two ESRs (ESRα and ESRβ), encoded by different genes, have been described (20). ESRα is expressed predominantly in the ovaries, uterus, testes and placenta, while ESRβ is expressed in numerous systems and tissues, including the central nervous, cardiovascular and immune systems and the urogenital and gastrointestinal tracts (21). In the uterus, there is a greater quantity of ESRα present than ESRβ. Also, it is now evident that ESRα is mainly involved in reproductive events (22). We therefore investigated the ESRα level (but not ESRβ) by RT-PCR and western blot analysis, and identified that ESRα mRNA and protein levels were increased significantly in comparison with normal pregnancies (P<0.05). ESRα is known to play a significant role in proliferation in the maturation of estrogen-dependent cells (23). Eissa et al stated that significantly enhanced ESR expression is exhibited in term deciduas from females with sPE, which indicates a unique role for ESR in pregnancy (8). Since the trophoblast is a major source of placental hormones, ESRα expression by trophoblast cells may be involved in the stimulation of placental hormonal estrogen production. We observed a significant decrease in the expression of estradiol in patients with sPE, whereas the increased ESRα expression may be a compensatory mechanism in these cases.

It should be noted that there are two existing forms of preeclampsia: early-onset (symptoms at <34 weeks, type I) and late-onset (symptoms at >34 weeks, type II). Early-onset preeclampsia is associated with placental risk factors, while late-onset preeclampsia is associated with the female etiology connected with disturbances in factors regulating inflammatory process, implantation and placentation (24). As placental tissues of <34 weeks of gestation were not easily obtainable, we used placental tissues of 36±2.7 weeks gestation (Table I) in the present study. Further investigation is required to clarify the differences in estradiol and ESRα expression between early-onset and late-onset preeclampsia.

Further studies have been carried out by our study group in order to unravel the mechanisms of upregulating ESRα expression in preeclamptic placentas. We have been focused on miRNAs, noncoding RNA molecules of 21 to 24 nt that regulate the expression of target genes in a post-transcriptional manner (25). We have carried out a comparison between the miRNA expression profiles of the PE placentas and the controls. Through microarray analysis and real time RT-PCR confirmation, we have identified certain miRNAs that are differently expressed in PE placentas, and from using computational target predictions we have also identified that the targets of these miRNAs included ESRα (3), suggesting that miRNAs were potentially involved in the regulation of ESRα expression. Further studies using miRNAs and ESRα are currently ongoing in our group.

In summary, estradiol expression was demonstrated to be significantly lowered in preeclamptic pregnancies, while we observed a significant increase in the expression of ESRα for patients with sPE. Our findings suggest that estradiol and ESRα may be involved in placentation and may be factors in the etiology of PE.

**Acknowledgements**

This study was supported in part by the Chinese Natural Science Foundation, Grants No. 31000660 (X.-M.Z.) and No. 30973208 (G.-W.Y.) and the Tangdu Hospital Elite Talent Fund (X.-M.Z.).

**References**


